{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-030447","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.234471+00:00","generated_at":"2026-06-01T04:00:46.968699+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ionis expands Otsuka license for donidalorsen in Asia-Pacific; $20M upfront","bullets":["Otsuka gains exclusive rights to commercialize donidalorsen (HAE) in Asia-Pacific; Ionis retains US rights.","Ionis receives $20M upfront, plus milestone payments and tiered royalties similar to the Europe deal.","Ionis plans to file U.S. NDA for donidalorsen in 2024 and launch independently if approved.","Otsuka will handle Asia-Pacific and Europe regulatory filings and commercialization; Ionis leads global development.","Positive Phase 3 OASIS-HAE and OASISplus results were recently published in NEJM."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-030447","json":"https://secwatch.observer/filing/0001140361-24-030447.json","markdown":"https://secwatch.observer/filing/0001140361-24-030447.md","text":"https://secwatch.observer/filing/0001140361-24-030447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036124030447/0001140361-24-030447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036124030447/ef20031301_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:00:46.968699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}